6-K
Partnerre Ltd (PREJF)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant To Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of August 2023
Commission File Number 001-14536
PartnerRe Ltd.
(Translation of registrant’s name into English)
Wellesley House South, 90 Pitts Bay Road,
Pembroke HM08, Bermuda
(441) 292-0888
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ý Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1).
Yes ¨ No ý
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7).
Yes ¨ No ý
DOCUMENTS FURNISHED AS PART OF THIS FORM 6-K
The following documents, furnished as exhibits to this Form 6-K, are incorporated by reference as part of this Form 6-K:
| Exhibit | Description of Exhibit |
|---|---|
| 99.1 | Press Release and Supplementary Financial Information – PartnerRe Ltd. first half 2023 results, dated August 1, 2023 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| PartnerRe Ltd. | |||
|---|---|---|---|
| (Registrant) | |||
| Date: | August 1, 2023 | By: | /s/ Abina Kealy |
| Name: Abina Kealy | |||
| Title: Chief Financial Officer |
EXHIBIT INDEX
| Exhibit | Description of Exhibit |
|---|---|
| 99.1 | Press Release and Supplementary Financial Information – PartnerRe Ltd. first half 2023 results, dated August 1, 2023 |
Document
Exhibit 99.1
News Release
PartnerRe Ltd. Reports First Half 2023 Results
PEMBROKE, Bermuda, August 1, 2023 - PartnerRe Ltd. ("the Company") today reported first half 2023 results.
Highlights
▪Net income attributable to common shareholder of $783 million, an improvement of $1,786 million, for an annualized return on equity of 23.9%
▪Operating income of $636 million for an annualized operating income return on equity of 19.5%, a 4.1% improvement
▪Net premiums earned grew by 10% reflecting 6% growth in P&C, 7% growth in Specialty and 21% growth in Life and Health
▪Non-life underwriting result was $466 million, with a combined ratio of 83.5%
▪Life and health allocated underwriting result of $78 million
▪Net investment return of $481 million included unrealized gains on fixed maturities and short-term investment of $107 million and an improvement in net investment income of 57%
▪Cash flows from operating activities of $1,084 million, reflecting growth of 58%
▪Long Duration Targeted Improvements ("LDTI") accounting standard adopted in Q1 2023; comparable periods have been updated to reflect the adoption
PartnerRe President and Chief Executive Officer Jacques Bonneau commented,
"Favorable market conditions persist half way through 2023, and we remain focused on our disciplined approach to capitalizing on these opportunities and making a meaningful contribution to the Covéa group. Our operating income of $636 million for the first half of 2023 continued its growth trend, up 24% compared to the first half of 2022. The fundamentals across operating segments are strong. For the non-life business we saw an improvement in current underwriting year performance for both the P&C and Specialty segments as compared to the first half of 2022, though the non-life combined ratio increased marginally by 1.6 points, as the first half of 2022 benefited from favorable prior year reserve development. The contribution from the Life and Health business continues to be a positive source of earnings to the group as premium volume grows. Our investment portfolio also performed well, demonstrated by 57% growth in net investment income compared to the first half of 2022, and we expect this trend to continue as we deploy our increasing cash flows from operations at attractive reinvestment rates."
| Operating income and operating income return on equity are non-GAAP financial measures. See "Non-GAAP Financial Measures - Regulation G" for a reconciliation of non-GAAP measures. | |
|---|---|
| Life and health allocated underwriting result includes net premiums earned, loss and loss expenses, acquisition costs, other income, other expense and allocated net investment income | |
| PartnerRe Ltd.<br><br>Wellesley House, 5th Floor<br><br>90 Pitts Bay Road<br><br>Pembroke, Bermuda HM 08 | Telephone +1 441 292 0888<br><br>Fax +1 441 292 6080<br><br>www.partnerre.com |
| --- | --- |
1
Consolidated Statements of Operations and
Comprehensive Income (Loss)
(Expressed in thousands of U.S. dollars) (Unaudited)
| For the six months ended | ||||
|---|---|---|---|---|
| June 30, 2023 | June 30, 2022 (1) | |||
| Revenues | ||||
| Gross premiums written | $ | 5,338,876 | $ | 4,976,886 |
| Net premiums written | $ | 4,540,383 | $ | 4,253,856 |
| Increase in unearned premiums | (690,012) | (748,081) | ||
| Net premiums earned | 3,850,371 | 3,505,775 | ||
| Net investment income | 285,741 | 182,571 | ||
| Net realized and unrealized investment gains (losses) | 198,006 | (1,725,356) | ||
| Other income | 14,697 | 18,123 | ||
| Total revenues | 4,348,815 | 1,981,113 | ||
| Expenses | ||||
| Losses and loss expenses (liability remeasurement loss (gain): 2023, $8,298; 2022, $(87,903)) | 2,455,919 | 2,146,598 | ||
| Market risk benefit gains | (19,649) | (109,147) | ||
| Acquisition costs | 788,351 | 750,881 | ||
| Other expenses | 216,401 | 183,498 | ||
| Interest expense | 28,638 | 27,492 | ||
| Amortization of intangible assets | 3,994 | 4,502 | ||
| Net foreign exchange losses (gains) | 20,711 | (21,103) | ||
| Total expenses | 3,494,365 | 2,982,721 | ||
| Income (loss) before taxes and interest in (loss) earnings of equity method investments | 854,450 | (1,001,608) | ||
| Income tax expense | (64,110) | (13,550) | ||
| Interest in (losses) earnings of equity method investments | (2,899) | 16,393 | ||
| Net income (loss) | 787,441 | (998,765) | ||
| Preferred dividends | 4,875 | 4,876 | ||
| Net income (loss) attributable to common shareholder | $ | 782,566 | $ | (1,003,641) |
| Comprehensive income (loss) | ||||
| Net income (loss) | $ | 787,441 | $ | (998,765) |
| Change in currency translation adjustment | 18,769 | (15,593) | ||
| Change in net unrealized gains or losses on investments, net of tax | (26) | — | ||
| Change in unfunded pension obligation, net of tax | 182 | 266 | ||
| Changes in discount rate for liability for future policy benefits, net of tax | 12,449 | 104,723 | ||
| Changes in instrument-specific credit risk for market risk benefits, net of tax | 2,671 | 44,570 | ||
| Comprehensive income (loss) | $ | 821,486 | $ | (864,799) |
(1) Amounts have been adjusted to reflect the adoption of LDTI.
Consolidated Balance Sheets (Expressed in thousands of U.S. dollars, except parenthetical share data) (Unaudited)
| June 30, 2023 | December 31, 2022 (1) | |||
|---|---|---|---|---|
| Assets | ||||
| Investments: | ||||
| Fixed maturities, at fair value | $ | 13,964,101 | $ | 13,021,914 |
| Short-term investments, at fair value | 837,180 | 523,510 | ||
| Equities, at fair value | 853,343 | 929,886 | ||
| Investments in real estate | 60,778 | 57,984 | ||
| Other invested assets | 3,674,220 | 3,355,106 | ||
| Total investments | 19,389,622 | 17,888,400 | ||
| Cash and cash equivalents | 1,086,550 | 1,251,596 | ||
| Accrued investment income | 120,644 | 103,752 | ||
| Reinsurance balances receivable | 4,340,327 | 3,342,612 | ||
| Reinsurance recoverable on paid and unpaid losses | 2,020,401 | 1,947,786 | ||
| Prepaid reinsurance premiums | 557,784 | 247,276 | ||
| Funds held by reinsured companies | 459,947 | 471,570 | ||
| Deferred acquisition costs | 1,095,641 | 1,012,067 | ||
| Market risk benefit assets | 152,337 | 131,186 | ||
| Deposit assets | 73,127 | 81,053 | ||
| Net tax assets | 118,618 | 177,189 | ||
| Goodwill | 456,380 | 456,380 | ||
| Intangible assets | 85,821 | 89,769 | ||
| Other assets | 225,422 | 203,119 | ||
| Total assets | $ | 30,182,621 | $ | 27,403,755 |
| Liabilities | ||||
| Non-life reserves | $ | 12,876,953 | $ | 12,725,631 |
| Life and health reserves | 2,786,947 | 2,497,519 | ||
| Market risk benefit liabilities | 4,187 | 9,170 | ||
| Unearned premiums | 3,753,380 | 2,745,371 | ||
| Other reinsurance balances payable | 1,056,402 | 632,336 | ||
| Debt | 1,867,223 | 1,848,003 | ||
| Deposit liabilities | 4,790 | 4,681 | ||
| Net tax liabilities | 66,217 | 55,131 | ||
| Accounts payable, accrued expenses and other (2) | 652,591 | 488,593 | ||
| Total liabilities | 23,068,690 | 21,006,435 | ||
| Shareholders’ Equity | ||||
| Common shares (par value $0.00000001; issued and outstanding: 100,000,000 shares) | — | — | ||
| Preferred shares (par value $1.00; issued and outstanding: 8,000,000 shares; aggregate liquidation value: $200,000) | 8,000 | 8,000 | ||
| Additional paid-in capital | 1,929,934 | 1,929,934 | ||
| Accumulated other comprehensive income | 105,356 | 71,311 | ||
| Retained earnings | 5,070,641 | 4,388,075 | ||
| Total shareholders’ equity | 7,113,931 | 6,397,320 | ||
| Total liabilities and shareholders’ equity | $ | 30,182,621 | $ | 27,403,755 |
(1) Amounts have been adjusted to reflect the adoption of LDTI.
(2) Includes payables for securities purchased of $268 million as at June 30, 2023 compared to $149 million as at December 31, 2022.
Non-GAAP Financial Measures - Regulation G
In addition to the GAAP financial measures set forth herein, the Company has also included certain non-GAAP financial measures within the meaning of Regulation G. Management believes that these non-GAAP financial measures are useful to investors and other stakeholders and help provide a consistent basis for comparison between quarters and for comparison with other companies within the industry. These measures may not, however, be comparable to similarly titled measures used by other companies outside of the insurance industry. These non-GAAP measures should be considered an addition to, and not a substitute for, measures of financial performance prepared in accordance with GAAP and investors are cautioned not to place undue reliance on these non-GAAP measures in assessing the Company’s overall financial performance. The reconciliation of non-GAAP financial measures to the most comparable GAAP financial measures in accordance with Regulation G is included within the relevant tables.
Operating Income (Loss) available to Common Shareholder (Operating Income (Loss)); Annualized Operating Return on Average Common Shareholder's Equity (Annualized Operating ROE): The Company uses Operating income (loss) and Annualized Operating ROE to measure performance, as these measures focus on the underlying fundamentals of the Company’s operations. Operating income (loss) is calculated after preferred dividends and excludes the impact of market risk benefit gains (losses), net realized and unrealized gains and losses on investments, net foreign exchange gains and losses, interest in earnings (losses) of equity method investments, favorable or adverse prior years' reserves development for which we have ceded the risk under an adverse development cover (ADC) and related changes in amortization of the deferred gain, the impact of non-recurring transactions such as losses on the redemption of preferred shares, and the cumulative tax effects of these adjustments. The Company calculates Annualized Operating ROE using Operating income (loss) for the period divided by the average common shareholder's equity outstanding for the period. Operating income (loss) should not be viewed as a substitute for Net Income (Loss) prepared in accordance with GAAP. Annualized Operating ROE supplements GAAP information. The Company's management believes that Operating income (loss) is useful to stakeholders because it more accurately reflects the underlying fundamentals of the business by removing the variability arising from activity that is largely independent of its business and underwriting processes, such as: fluctuations in the fair value of market risk benefit assets and liabilities; the fluctuations in the fair value of the Company's investment portfolio; fluctuations in foreign exchange rates; fluctuations of returns on the Company's equity method investments; the impact of retroactive reinsurance agreements where the Company believes adjusting for this development shows the ultimate economic benefit of the ADC; and the impact of non-recurring transactions such as losses on the redemption of preferred shares
| For the six months ended | ||||||||
|---|---|---|---|---|---|---|---|---|
| June 30, 2023 | June 30, 2022 (1) | |||||||
| ROE (2) | ROE (2) | |||||||
| Net income (loss) attributable to common shareholder | 23.9 | % | (30.3) | % | ||||
| Less: adjustments for non-operating items | ||||||||
| Market risk benefit gains | 19,649 | 0.6 | 109,147 | 3.3 | ||||
| Net realized and unrealized investment gains (losses) | 198,006 | 6.0 | (1,725,356) | (52.0) | ||||
| Net foreign exchange (losses) gains | (20,711) | (0.6) | 21,103 | 0.6 | ||||
| Interest in (losses) earnings of equity method investments | (2,899) | (0.1) | 16,393 | 0.5 | ||||
| Adverse prior years' reserve development subject to ADC | (61,949) | (1.9) | (30,571) | (0.9) | ||||
| Tax effects of adjustments | 14,631 | 0.4 | 90,822 | 2.7 | ||||
| Operating income | 19.5 | % | 15.4 | % |
All values are in US Dollars.
| For the six months ended | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Calculation of average common shareholder's equity | June 30, 2023 | June 30, 2022 (1) | ||||||||
| Beginning of period common shareholder's equity | $ | 6,197,320 | $ | 7,157,428 | ||||||
| End of period common shareholder's equity | $ | 6,913,931 | $ | 6,109,859 | ||||||
| Average common shareholder's equity | $ | 6,555,626 | $ | 6,633,644 | As at June 30, 2023 | As at December 31, 2022 (1) | ||||
| --- | --- | --- | --- | --- | ||||||
| Total shareholders' equity | $ | 7,113,931 | $ | 6,397,320 | ||||||
| Less: Preferred shares, aggregate liquidation value at $25 per share | 200,000 | 200,000 | ||||||||
| Common shareholder’s equity or book value | $ | 6,913,931 | $ | 6,197,320 | ||||||
| Capital structure: | ||||||||||
| Total debt | $ | 1,867,223 | $ | 1,848,003 | ||||||
| Preferred shares, aggregate liquidation value | 200,000 | 200,000 | ||||||||
| Common shareholder's equity | 6,913,931 | 6,197,320 | ||||||||
| Total capital | $ | 8,981,154 | $ | 8,245,323 |
(1) Amounts have been adjusted to reflect the adoption of LDTI.
(2) ROE is calculated as net income or loss attributable to common shareholder divided by average common shareholder's equity, annualized for the period. The average common shareholder's equity is calculated using the sum of the beginning of period and end of period common shareholder's equity divided by two.
Please refer to the "Financial Information - Annual Reports" section of the Company's website for a copy of the Company's Annual Report on Form 20-F at: www.partnerre.com/financial-information/annual-reports/. Forward-looking statements contained in this press release, such as those related to company performance, are based on the Company’s assumptions and expectations concerning future events and financial performance and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to significant business, economic and competitive risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. PartnerRe’s forward-looking statements could be affected by numerous foreseeable and unforeseeable events and developments such as exposure to catastrophe, pandemic or other large property and casualty losses, credit, interest, currency and other risks associated with the Company’s investment portfolio, adequacy of reserves, levels and pricing of new and renewal business achieved, changes in accounting policies, risks associated with implementing business strategies, and other factors identified in the Company’s reports filed or furnished with the Securities and Exchange Commission. In light of the significant uncertainties inherent in the forward-looking information contained herein, readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the dates on which they are made. The Company disclaims any obligation to publicly update or revise any forward-looking information or statements. The Company’s estimate for recent catastrophic and pandemic losses is based on a preliminary analysis of the Company’s exposures, the current assumption of total insured industry losses and preliminary information received from certain cedants to date. There is material uncertainty associated with the Company's loss estimates given the nature, magnitude and recency of these loss events and the limited claims information received to date. The ultimate loss therefore may differ materially from the current preliminary estimate.
Contacts: PartnerRe Ltd. (441) 292-0888
Investor Contact: Stephen Boylan
Media Contact: Elizabeth Deacon
partnerre.com
5